Literature DB >> 28934736

Reduced Drinking in Alcohol Dependence Treatment, What Is the Evidence?

Karl Mann1, Henri-Jean Aubin, Katie Witkiewitz.   

Abstract

Abstinence from alcohol has been the prevailing treatment goal for individuals with alcohol dependence (AD) within the context of specialty alcohol treatment. Yet, alcohol use has been conceptualized as existing on a continuum. Importantly, most people who meet criteria for AD and could benefit from treatment never receive treatment. About half of these individuals do not seek treatment because they report a desire to continue drinking. To increase acceptability of treatment, reductions in alcohol consumption have been examined as alternative outcomes in treatment trials for AD. The current study reviews data which indicate that long-term reduction in alcohol consumption among patients with AD is possible. Controlled studies have tested reduced alcohol consumption and show sustained improvements in drinking reductions for many patients following behavioral treatments and pharmacotherapy. Evidence-based treatment guidelines and medicines development guidance authorities have taken note of these developments and accept "intermediate harm reduction" (European Medicines Agency) or "low-risk drinking limits" (US Federal Drug Administration) as optional trial endpoints. In conclusion, while abstinence remains the safest treatment goal for individuals with AD, evidence supports that reduced drinking approaches may be an important extension in the treatment of AD.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Alcohol dependence; Controlled drinking; Harm reduction; Pharmacotherapy; Reduced drinking

Mesh:

Year:  2017        PMID: 28934736     DOI: 10.1159/000481348

Source DB:  PubMed          Journal:  Eur Addict Res        ISSN: 1022-6877            Impact factor:   3.015


  22 in total

1.  Drinking Risk Level Reductions Associated with Improvements in Physical Health and Quality of Life Among Individuals with Alcohol Use Disorder.

Authors:  Katie Witkiewitz; Henry R Kranzler; Kevin A Hallgren; Stephanie S O'Malley; Daniel E Falk; Raye Z Litten; Deborah S Hasin; Karl F Mann; Raymond F Anton
Journal:  Alcohol Clin Exp Res       Date:  2018-11-05       Impact factor: 3.455

2.  Reduction in non-abstinent World Health Organization (WHO) drinking risk levels and drug use disorders: 3-year follow-up results in the US general population.

Authors:  Justin Knox; Melanie Wall; Katie Witkiewitz; Henry R Kranzler; Daniel E Falk; Raye Litten; Karl Mann; Stephanie S O'Malley; Jennifer Scodes; Raymond Anton; Deborah S Hasin
Journal:  Drug Alcohol Depend       Date:  2019-05-29       Impact factor: 4.492

3.  Drink goal difficulty effect on outcomes in moderation-based alcohol treatment for sexual minority men.

Authors:  Svetlana Levak; Alexis N Kuerbis; Jon Morgenstern
Journal:  J Subst Abuse Treat       Date:  2020-01-09

4.  Reduction in non-abstinent WHO drinking risk levels and depression/anxiety disorders: 3-year follow-up results in the US general population.

Authors:  Justin Knox; Jennifer Scodes; Melanie Wall; Katie Witkiewitz; Henry R Kranzler; Daniel Falk; Raye Litten; Karl Mann; Stephanie S O'Malley; Raymond Anton; Deborah S Hasin
Journal:  Drug Alcohol Depend       Date:  2019-02-14       Impact factor: 4.492

Review 5.  Prevention, screening, and treatment for heavy drinking and alcohol use disorder.

Authors:  Justin Knox; Deborah S Hasin; Farren R R Larson; Henry R Kranzler
Journal:  Lancet Psychiatry       Date:  2019-10-17       Impact factor: 27.083

6.  World Health Organization risk drinking level reductions are associated with improved functioning and are sustained among patients with mild, moderate and severe alcohol dependence in clinical trials in the United States and United Kingdom.

Authors:  Katie Witkiewitz; Nick Heather; Daniel E Falk; Raye Z Litten; Deborah S Hasin; Henry R Kranzler; Karl F Mann; Stephanie S O'Malley; Raymond F Anton
Journal:  Addiction       Date:  2020-03-10       Impact factor: 6.526

7.  Reduction in World Health Organization Risk Drinking Levels and Cardiovascular Disease.

Authors:  Justin Knox; Jennifer Scodes; Katie Witkiewitz; Henry R Kranzler; Karl Mann; Stephanie S O'Malley; Melanie Wall; Raymond Anton; Deborah S Hasin
Journal:  Alcohol Clin Exp Res       Date:  2020-07-03       Impact factor: 3.455

8.  What defines a clinically meaningful outcome in the treatment of substance use disorders: reductions in direct consequences of drug use or improvement in overall functioning?

Authors:  Brian D Kiluk; Garrett M Fitzmaurice; Eric C Strain; Roger D Weiss
Journal:  Addiction       Date:  2018-06-27       Impact factor: 6.526

9.  Abstinence and low risk drinking during treatment: Association with psychosocial functioning, alcohol use, and alcohol problems 3 years following treatment.

Authors:  Katie Witkiewitz; Megan Kirouac; Corey R Roos; Adam D Wilson; Kevin A Hallgren; Adrian J Bravo; Kevin S Montes; Stephen A Maisto
Journal:  Psychol Addict Behav       Date:  2018-08-30

10.  Reduction in Nonabstinent WHO Drinking Risk Levels and Change in Risk for Liver Disease and Positive AUDIT-C Scores: Prospective 3-Year Follow-Up Results in the U.S. General Population.

Authors:  Justin Knox; Melanie Wall; Katie Witkiewitz; Henry R Kranzler; Daniel Falk; Raye Litten; Karl Mann; Stephanie S O'Malley; Jennifer Scodes; Raymond Anton; Deborah S Hasin
Journal:  Alcohol Clin Exp Res       Date:  2018-10-03       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.